Gene diversification by directed retrotransposition

Information

  • Research Project
  • 6443039
  • ApplicationId
    6443039
  • Core Project Number
    R43GM065044
  • Full Project Number
    1R43GM065044-01
  • Serial Number
    65044
  • FOA Number
  • Sub Project Id
  • Project Start Date
    2/8/2002 - 24 years ago
  • Project End Date
    8/7/2002 - 23 years ago
  • Program Officer Name
    WOLFE, PAUL B.
  • Budget Start Date
    2/8/2002 - 24 years ago
  • Budget End Date
    8/7/2002 - 23 years ago
  • Fiscal Year
    2002
  • Support Year
    1
  • Suffix
  • Award Notice Date
    2/8/2002 - 24 years ago
Organizations

Gene diversification by directed retrotransposition

DESCRIPTION (provided by applicant): Gene-products of recombinant origin have substantial commercial value for pharmaceutical and technical uses. Directed evolution approaches to generate new or improved products have successfully been applied in instances where structure-function data for target molecules are limited. Current approaches use in vitro techniques to generate diversity. These methods have a number of shortcomings due to expense and difficulty in creation of large molecular diversity libraries containing new variants. The use of a concerted in vivo process that generates large libraries of cells producing variants of the starting molecule, would result in considerable cost and effort savings. The fungus Neurospora crassa has the ability to correctly express, fold, modify and secrete active eukaryotic proteins, and the ability to "shuffle" DNA sequences in vivo by high-frequency meiotic gene conversion. The addition of a method to induce targeted mutations into an expressed heterologous gene would allow rapid screening of new variants, with no additional molecular manipulations. This proposal investigates the potential to use directed retrotransposition to introduce mutation into heterologous sequences in this fungus. Experiments to demonstrate controlled transduction of transposon-reporter chimeras between genetically marked nuclei will be performed. The long term outcome of this proposal is to generate molecular diversity in target genes, for screening of new activities and products. PROPOSED COMMERCIAL APPLICATION: This proposal tests a new method for in vivo diversification of genes by retrotransposition. This error-prone process may then be used to generate simple and robust molecular diversity libraries for screening of new variants of commercially valuable gene-products. Success will lead to a novel alternative method for directed evolution of new or improved products, allowing entry into markets for new pharmaceutical, industrial and agricultural products.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R43
  • Administering IC
    GM
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    100000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    821
  • Ed Inst. Type
  • Funding ICs
    NIGMS:100000\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    NEUGENESIS CORPORATION
  • Organization Department
  • Organization DUNS
  • Organization City
    BURLINGAME
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    94010
  • Organization District
    UNITED STATES